Dr. Christopher W. Ryan
Claim this profileOregon Health and Science University
Expert in Cancer
Studies Tumors
22 reported clinical trials
70 drugs studied
About Christopher W. Ryan
Education:
- Earned an MD (Doctor of Medicine) from an unspecified institution.
Experience:
- Completed Residency in Internal Medicine at the University of Chicago in 1997.
- Completed Fellowship in Hematology/Oncology at the University of Chicago in 2000.
- Certified by the American Board of Internal Medicine (Medical Oncology) since 2000.
- Member of the American Society of Clinical Oncology.
- Specializes in the treatment of sarcomas and genitourinary cancers.
- Actively involved in providing patients with the latest treatments through clinical trials.
Area of expertise
1Cancer
Global LeaderStage IV
Stage III
HER2 positive
2Tumors
Stage IV
Stage III
PD-L1 positive
Affiliated Hospitals
Clinical Trials Christopher W. Ryan is currently running
Cemiplimab + Palbociclib
for Liposarcoma
This phase II trial compares the effect of treatment with palbociclib alone to treatment with palbociclib plus cemiplimab for treating patients with dedifferentiated liposarcoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Palbociclib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Cemiplimab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. The combination of these two drugs may be more effective in shrinking or stabilizing advanced dedifferentiated liposarcoma compared to palbociclib alone.
Recruiting1 award Phase 2
ACR-368
for Ovarian Cancer
This trial tests a new drug, ACR-368, alone or with a small dose of another drug, gemcitabine, in patients whose cancers don't respond to standard treatments. A special test helps decide which treatment might work best for each patient. Gemcitabine has been used with other drugs for various cancers, including pancreatic, lung, ovarian, and breast cancers.
Recruiting1 award Phase 1 & 210 criteria
More about Christopher W. Ryan
Clinical Trial Related3 years of experience running clinical trials · Led 22 trials as a Principal Investigator · 9 Active Clinical TrialsTreatments Christopher W. Ryan has experience with
- Nivolumab
- Ipilimumab
- Pembrolizumab
- Gemcitabine
- Placebo
- Paclitaxel
Breakdown of trials Christopher W. Ryan has run
Cancer
Tumors
Bladder Cancer
Renal Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Christopher W. Ryan specialize in?
Christopher W. Ryan focuses on Cancer and Tumors. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Christopher W. Ryan currently recruiting for clinical trials?
Yes, Christopher W. Ryan is currently recruiting for 9 clinical trials in Portland Oregon. If you're interested in participating, you should apply.
Are there any treatments that Christopher W. Ryan has studied deeply?
Yes, Christopher W. Ryan has studied treatments such as Nivolumab, Ipilimumab, Pembrolizumab.
What is the best way to schedule an appointment with Christopher W. Ryan?
Apply for one of the trials that Christopher W. Ryan is conducting.
What is the office address of Christopher W. Ryan?
The office of Christopher W. Ryan is located at: Oregon Health and Science University, Portland, Oregon 97239 United States. This is the address for their practice at the Oregon Health and Science University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.